Journal Article

Practical considerations in the use of regorafenib in metastatic colorectal cancer

Pietrantonio, Filippo, Bekaii-Saab, Tanios, Yuki, Satoshi, Xu, Rui-Hua, Macarulla, Teresa, Winder, Thomas, Bachet, Jean-Baptiste, Antonuzzo, Lorenzo, Loupakis, Fotios, Kuan, Feng-Che, Zeng, Shan, Taniguchi, Hiroya

2020

Overview

Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician–patient communication points to facilitate shared decision-making.

• Publisher: SAGE Publications,Sage Publications Ltd,SAGE Journals,SAGE Publishing
• Subject: [SDV]Life Sciences [q-bio] / adverse events / adverse events; metastatic colorectal cancer; practical management; regorafenib; third line / Colorectal cancer / Còlon - Càncer - Tractament / Decision making / Diagnosis::Clinical Decision-Making [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] / diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] / enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-tirosina cinasas [COMPUESTOS QUÍMICOS Y DROGAS] / Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases [CHEMICALS AND DRUGS] / Inhibitor drugs / Life Sciences / Metastases / Metastasis / metastatic colorectal cancer / neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] / Neoplasms. Tumors. Oncology. Including cancer and carcinogens / Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] / Other subheadings::Other subheadings::/antagonists & inhibitors [Other subheadings] / Otros calificadores::Otros calificadores::/antagonistas & inhibidores [Otros calificadores] / Patients / practical management / Proteïnes quinases - Inhibidors - Ús terapèutic / RC254-282 / Recte - Càncer - Tractament / regorafenib / Review / Shared decision making / Targeted cancer therapy / third line